CoLucid raises $7.5M for Phase II oral migraine therapy
This article was originally published in Scrip
Executive Summary
CoLucid Pharmaceuticals, a US biotech company founded in 2005 by Pappas Ventures to focus on CNS disorders, has raised $7.5 million of a planned $9.5 million convertible note to take the company's lead product candidate, the novel migraine treatment lasmiditan (COL-144), into late-stage development. It is speaking with potential partners, and plans to move the compound into Phase III studies in 2012.